AbbVie Says “V” Is For V-Shaped Recovery
Q2 Victories Include Botox Rebound, Big Skyrizi, Rinvoq Gains
Executive Summary
The firm’s major product revenues bounced back from the pandemic-troubled second quarter, with Botox recovering as predicted.
You may also be interested in...
Keeping Track: Provention Teplizumab, AZ Anifrolumab Headline Submissions; AZ Brilinta Gains Stroke Risk Reduction Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
AbbVie Investors Look For Stabilizing Botox Revenues In Q3 Financials
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.
AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials
AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports